United Therapeutics Stock News & Updates

[WKN: 923818 | Symbol: UTHR]

United Therapeutics: TETON Breakthrough and EPS Beat Drive Record Rally

Clinical Milestone: The stock is shooting up on high volume after the TETON-1 study for Tyvaso in...

United Therapeutics: From Niche Player to Giant in Organ Technology

With the excellent study data from March 30, 2026, United Therapeutics is on the brink of tapping into...

United Therapeutics: TETON-1 Study for Idiopathic Pulmonary Fibrosis Offers Revenue Opportunity of $3.3 Billion!

United Therapeutics (UTHR) specializes in the treatment of rare lung diseases with its core product Tyvaso...

United Therapeutics (UTHR) in our Pivotal Point Check: Study Breakthrough in Pulmonary Fibrosis and $2 Billion Buyback Program Cause an all-Time High!

TETON-1 study exceeds expectations: The drug Tyvaso shows significant improvement in lung function...

Stocks in Action USA: Insmed, Alcoa, United Therapeutics

Insmed (INSM) – Biotech Stock Poised for Rebound: Analysts Fuel Momentum with 45% Price Potential!...

United Therapeutics: TreSMI Shakes up the Rare Lung Disease Market

United Therapeutics (UTHR) is likely to maintain its trend for several reasons. With Tyvaso, the company...

United Therapeutics: Tyvaso Study Data Represents a new $5.4 Billion Opportunity – the Stock Reaches a new all-Time High!

United Therapeutics (UTHR) aims to reach a total revenue of $16 billion by 2030 through the treatment...

  • 1